1型和2型拟除虫菊酯中毒的临床表现
结果显示两型恶心呕吐和震颤发生率相似,但2型感觉异常(32.6% vs 6.2%)、流涎(20.9% vs 0%)、意识模糊(18.6% vs 0%)更常见。24例血清检出拟除虫菊酯,22例可定量(1.1–453 μg/ml)。2例需插管,全部存活,中位住院12小时。摄入2型(尤其是高效氯氟氰菊酯)和摄入量大与中重度毒性相关。
要点
- 2型拟除虫菊酯中毒者感觉异常(32.6% vs 6.2%,p=0.04)、流涎(20.9% vs 0%,p=0.04)、意识模糊(18.6% vs 0%,p=0.03)比1型更常见。
- 摄入2型拟除虫菊酯(尤其是高效氯氟氰菊酯)与中重度毒性相关(OR 7.81,95%CI 1.55–39.37,p=0.01)。
- 摄入量越大中重度毒性风险越高(OR 1.01,95%CI 1.00–1.02,p=0.02)。
- 恶心呕吐(81.2% vs 81.3%)和震颤(37.5% vs 32.6%)在1型和2型中毒中发生率相似。
适用人群与场景
- 拟除虫菊酯中毒患者,分为1型(16例)和2型(43例)中毒两组;为急诊就诊的中毒患者,具体纳入/排除标准原文未提及。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 意识水平降低和呼吸窘迫是需要插管的指征:2例(高效氯氟氰菊酯中毒和氯氰菊酯中毒)因低意识和呼吸窘迫需插管。
- 2型拟除虫菊酯中毒者出现意识模糊(18.6% vs 0%,p=0.03)、流涎(20.9% vs 0%,p=0.04)、感觉异常(32.6% vs 6.2%,p=0.04)更频繁,需警惕。
- 摄入2型拟除虫菊酯(尤其高效氯氟氰菊酯)或摄入量大者中重度毒性风险更高(OR 7.81,95%CI 1.55–39.37;OR 1.01,95%CI 1.00–1.02)。
研究设计与关键结果
- 恶心呕吐(81.2% vs 81.3%)和震颤(37.5% vs 32.6%)发生率相似;2型感觉异常(32.6% vs 6.2%,p=0.04)、流涎(20.9% vs 0%,p=0.04)、意识模糊(18.6% vs 0%,p=0.03)更常见;癫痫发作(7% vs 0%,p=0.29)差异无统计学意义。
- 24例血清检出拟除虫菊酯,22例可定量,血清浓度范围1.1–453 μg/ml;35例未检出。
- 2例需插管(高效氯氟氰菊酯中毒和氯氰菊酯中毒),全部存活,中位住院12(12–24)小时。
- 中重度毒性的相关因素:摄入2型拟除虫菊酯(OR 7.81,95%CI 1.55–39.37,p=0.01)、高效氯氟氰菊酯(OR 7.81,95%CI 1.55–39.37,p=0.01)、摄入量(OR 1.01,95%CI 1.00–1.02,p=0.02)。
证据类型、等级与局限
- (本栏提炼含原文里核对不到的数值,已删除,请以原文为准)
对床旁实践的改变
- 拟除虫菊酯中毒总体以轻中度症状为主、预后良好,可据此安抚和分层,但2型中毒(尤其高效氯氟氰菊酯)或摄入量大者应警惕中重度毒性。
- 2型中毒者出现感觉异常、流涎、意识模糊更常见,评估时应关注这些表现;出现意识水平降低和呼吸窘迫需准备插管。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: It is unclear if the clinical presentation of poisoning with type 1 and type 2 pyrethroid compounds is different. This study was undertaken to detail the clinical profile and outcome of patients presenting with pyrethroid poisoning and to quantify serum pyrethroid levels.
PATIENTS AND METHODS: In this prospective study, patients were categorised as poisoning with type 1 pyrethroids or type 2 pyrethroids. Blood samples were sent for compound identification and quantification. Clinical features and outcomes were compared between the two groups. Factors associated with moderate and severe toxicity were explored using univariate logistic regression analysis and presented as odds ratio (OR) and 95% confidence intervals (CI).
RESULTS: Type 1 pyrethroids were implicated in 16 patients and type 2 in 43 patients. The incidence of nausea and vomiting (81.2% vs. 81.3%) and tremor (37.5% vs. 32.6%) were similar in type 1 and type 2 poisoning; paraesthesia (6.2% vs. 32.6%, p = 0.04), hypersalivation (0% vs. 20.9%, p = 0.04), seizures (0% vs. 7%, p = 0.29) and depressed sensorium (0% vs. 18.6%, p = 0.03.) were observed more frequently in type 2 pyrethroid poisoning. Pyrethroids were detected in the serum samples of 24 patients; quantification was possible in 22 patients in whom serum levels ranged from 1.1 to 453 μg/ml. The compounds were undetectable in 35 patients. Two patients (lambda-cyhalothrin poisoning and cypermethrin poisoning) required intubation for low sensorium and respiratory distress. The median (interquartile range) duration of hospitalization was 12 (12-24) hours. All patients survived. Factors associated with moderate and severe toxicity included ingestion of a type 2 pyrethroid, lambda-cyhalothrin (OR 7.81, 95%CI 1.55-39.37, p = 0.01) and volume ingested (OR 1.01, 95%CI 1.00-1.02, p = 0.02).
CONCLUSION: Patients with pyrethroid poisoning present predominantly with mild to moderate symptoms. Paraesthesia and hypersalivation are more frequent in type 2 poisoning. A favourable outcome can be expected.
参考来源
- Jacob MS, Iyyadurai R, Jose A, et al. Clinical presentation of type 1 and type 2 pyrethroid poisoning in humans. Clin Toxicol (Phila). 2021. PMID: 34672857. doi:10.1080/15563650.2021.1994145
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。